⌕
Rhythm Pharmaceuticals · RYTM · Nasdaq
Tenet 36 · Weak
Compare
$116.61+8.49%At closeTenet 36 · Weak
$116.61+9.13 (+8.49%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Rhythm Pharmaceuticals (RYTM) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~178.5%/yr (FY21→FY25), net margin −103.6%. Worth your attention in FY25: Share count (+31.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲45.8%
189.8
FY21→FY25CAGR +178.5%/yr
Net income ($M)▲24.6%
−196.5
FY21→FY25CAGR —
Free cash flow ($M)▼2.4%
−116.6
FY21→FY25CAGR —
Diluted EPS▲28.3%
−3.11
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+31.0%

49.6mn → 65.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)189.8Revenue−19.5COGS170.3Gross profit−167.3R&D−194.9SG&A−192.0Op income−4.5Tax & other−196.5Net income

-104¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 81.0% → 89.7%. Net margin -103.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
280,748.0189,757.0130,126.077,428.023,638.03,154.0▲45.8%+178.5%
Cost of revenue
33,056.019,492.013,368.09,302.02,133.0599.0▲45.8%+138.8%
Gross profit
247,692.0170,265.0116,758.068,126.021,505.02,555.0▲45.8%+185.7%
Research & development
179,665.0167,340.0237,957.0134,951.0108,630.0104,128.0▼29.7%+12.6%
Selling, general & admin
255,273.0194,941.0144,304.0117,532.092,032.068,486.0▲35.1%+29.9%
Total operating expenses
434,938.0362,281.0382,261.0252,483.0200,662.0172,614.0▼5.2%+20.4%
Operating incomefeeds ROC rank
−187,246.0−192,016.0−265,503.0−184,357.0−179,157.0−170,059.0▲27.7%—
Other income, net
−4,997.0−4,026.05,247.0243.0−1,962.0100,447.0——
Pretax income
−192,243.0−196,042.0−260,256.0−184,114.0−181,119.0−69,612.0▲24.7%—
Income tax
1,568.0497.0346.0564.00.00.0▲43.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−193,811.0−196,539.0−260,602.0−184,678.0−181,119.0−69,612.0▲24.6%—
Per share
Diluted EPSbuyback-sensitive
−2.90−3.11−4.34−3.200.00−1.40▲28.3%—
Diluted shares (mn)
69.0564.9861.0057.670.0049.60▲6.5%+7.0%
Margins
Gross margin83rd pct in Healthcare
88.2%89.7%89.7%88.0%91.0%81.0%▲0.0pp+8.7pp
Operating margin
−66.7%−101.2%−204.0%−238.1%−757.9%−5391.9%▲102.8pp+5290.7pp
Net margin11th pct in Healthcare
−69.0%−103.6%−200.3%−238.5%−766.2%−2207.1%▲96.7pp+2103.5pp
† TTM = trailing four quarters through 2026-09-30.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Rhythm Pharmaceuticals' revenue last fiscal year?

Rhythm Pharmaceuticals reported revenue of $189.8M in fiscal 2025, up 45.8% from fiscal 2024.

What was Rhythm Pharmaceuticals' net income?

Rhythm Pharmaceuticals reported net income of −$196.5M in fiscal 2025, a net margin of −103.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.